“I had treatment last year and I want to give something back.”
A study looking at eribulin for advanced breast cancer
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is to find out more about the chemotherapy drug eribulin as a treatment for breast cancer that has spread into the surrounding tissue (locally advanced) or to another part of the body (secondary breast cancer).
Doctors can treat locally advanced and secondary breast cancer with chemotherapy. One chemotherapy drug they use is eribulin. We know eribulin works, but not how well it works in practice.
In this study the researchers want to collect information about a group of people who are taking eribulin for their locally advanced or secondary breast cancer. This will include information about how you are doing, what other medications you are taking, any side effects and other treatments you may have.
The aims of this study are to find out
- How well eribulin works for people with locally advanced and secondary breast cancer
- How safe it is
Who can enter
You may be able to enter this trial if
- You are taking eribulin at the moment
- You have breast cancer that has spread to surrounding tissue (locally advanced) or has spread to another part of your body (secondary breast cancer)
- Your cancer came back after treatment with 1 or 2 different types of chemotherapy
- Your blood test results are satisfactory
- You are at least 18 years old
You cannot enter this trial if
- This isn’t the first time you have taken eribulin
- You have had treatment for locally advanced or secondary breast cancer with more than 2 different types of chemotherapy
This is a phase 4 study. It will recruit 150 people. Everyone will have eribulin.
While you are on the study, your cancer doctor will collect information about how you are doing, what other medications you are taking, any side effects and other treatments you may have as long as you are taking eribulin.
You remain part of the study as long as you are taking eribulin.
There are no extra visits to the hospital if you take part in this study.
How to join a clinical trial
Dr Hartmut Kristeleit
NIHR Clinical Research Network: Cancer